EP3958882A1 - Bakterium der familie christensenellaceae zur prävention und/oder behandlung von hypertriglyceridämie - Google Patents

Bakterium der familie christensenellaceae zur prävention und/oder behandlung von hypertriglyceridämie

Info

Publication number
EP3958882A1
EP3958882A1 EP20725761.9A EP20725761A EP3958882A1 EP 3958882 A1 EP3958882 A1 EP 3958882A1 EP 20725761 A EP20725761 A EP 20725761A EP 3958882 A1 EP3958882 A1 EP 3958882A1
Authority
EP
European Patent Office
Prior art keywords
bacterium
use according
composition
bacteria
hypertriglyceridemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20725761.9A
Other languages
English (en)
French (fr)
Inventor
Georges Rawadi
Sandrine Paule CLAUS
Laure RINALDI
Frédéric Elustondo
Marion Sophie Madeleine SOTO
Katy LECORF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verb Biotics
Original Assignee
Ysopia Biosciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1904346A external-priority patent/FR3095339A1/fr
Application filed by Ysopia Biosciences SA filed Critical Ysopia Biosciences SA
Publication of EP3958882A1 publication Critical patent/EP3958882A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

  • the invention relates to the treatment of hypertriglyceridemia with specific bacteria of the intestinal microbiota.
  • Triglycerides are lipids that allow the storage of fatty acids in adipose tissue. They can be hydrolyzed as needed to allow the release of fatty acids which are then used as an energy source.
  • Hypertriglyceridemia corresponds to an excess of circulating triglycerides, that is to say contained in the blood.
  • hypertriglyceridemia corresponds to an increase in circulating triglyceride levels beyond 150 mg / dL or 1.7 mmol / L according to the guidelines of NCEP ATP III, “American Heart Association”, “National Lipid Association”, “The Endocrine Society”, “the European Society of Cardiology” and “the European Atherosclerosis Society”.
  • NCEP ATP III “American Heart Association”, “National Lipid Association”, “The Endocrine Society”, “the European Society of Cardiology” and “the European Atherosclerosis Society”.
  • NCEP ATP III “American Heart Association”, “National Lipid Association”, “The Endocrine Society”, “the European Society of Cardiology” and “the European Atherosclerosis Society”.
  • NCEP ATP III “American Heart Association”, “National Lipid Association”, “The Endocrine Society”, “the European Society of Cardiology” and “the European Atherosclerosis Society”.
  • the disease can be
  • - secondary hypertriglyceridemia induced by drug treatments, excessive alcohol intake, bad eating habits, diabetes, endocrine diseases, kidney disease, hepatic disease, pregnancy or autoimmune disorders.
  • hypertriglyceridemia is a metabolic disorder commonly encountered in obese individuals, obesity is not the only cause of hypertriglyceridemia. It is therefore necessary to differentiate obesity as a disease associated with excess weight, and hypertriglyceridemia as a disease associated with an excess of circulating triglycerides, which makes them distinct pathological conditions.
  • hypertriglyceridemia is estimated at approximately 32% of the American population, including 18% above the limit of 200 mg / dL (moderate to severe hypertriglyceridemia).
  • Hypertriglyceridemia can be the cause of complications and cause the appearance of other pathologies. In fact, moderate hypertriglyceridemia is an important risk factor for the development of cardiovascular diseases, such as atherosclerosis. It is also known that one of the main pathologies associated with severe hypertriglyceridemia is acute pancreatitis. Currently, there are several types of treatments:
  • statins lipid-lowering drugs: they act mainly on the elevation of LDL-cholesterol but not on the elevation of triglycerides which has however been attributed to an increased risk of vascular accidents.
  • statins have significant side effects, mainly muscle pain. In some cases they have been shown to cause high blood sugar levels and precipitate type 2 diabetes.
  • Christensenella minuta Bacteria of the Christensenellaceae family, in particular of the genus Christensenella, have already been studied and described. This is the case in particular with Christensenella minuta, Christensenella massiliensis and Christensenella timonensis. Christensenella minuta in particular was first described in 2012. In 2014, a study showed that it was the most heritable taxon in a cohort of British twins and that their presence is associated with a body mass index. low. This correlation between Christensenella minuta and low body mass index was then observed in a dozen studies published since 2014 in geographically diverse populations.
  • the bacteria of the Christensenellaceae family in particular of the genus Christensenella, and in particular Christensenella minuta, when they are administered to humans or to animals, are capable of acting on the decrease in circulating triglycerides and lipoproteins (LDL, VLDL).
  • LDL circulating triglycerides and lipoproteins
  • the subject of the invention is a bacterium of the Christensenellaceae family, for its use in the prevention and / or treatment of hypertriglyceridemia in humans or animals.
  • such a bacterium when it is administered to a human being or an animal exhibiting hypertriglyceridemia, is capable of acting on the excess triglycerides in the organism and on the lipoproteins which allow their transport.
  • a subject of the invention is also the compositions comprising at least one bacterium of the Christensenellaceae family, for its use in the prevention and / or treatment of hypertriglyceridemia in humans or animals.
  • Figure 1 shows the quantification of triglycerides (Figure IA) and free fatty acids (Figure IB) of the liver of mice fed a diet rich in fat (HFD45%) having received a control solution (HFD-Veh) or a solution containing C minuta 10 9 CFU (HFD-C minuta) by daily gavage for 7 weeks.
  • Figure 2 shows the relative expression level of glucokinase (Gck) in the liver of mice fed a high fat diet (HFD45%) given a control solution (HFD-Veh) or a solution containing C. minuta 10 9 CFU (HFD-C minuta) by daily gavage for 4 weeks.
  • HFD45% high fat diet
  • HFD-Veh control solution
  • HFD-C minuta a solution containing C. minuta 10 9 CFU
  • a subject of the invention is therefore the use, in the prevention and / or treatment of hypertriglyceridemia in humans or animals, of at least one bacterium of the Christensenellaceae family.
  • the invention therefore relates to a bacterium of the Christensenellaceae family for its use in the prevention and / or treatment of hypertriglyceridemia, in particular in people or animals exhibiting secondary hypertriglyceridemia.
  • the bacteria are chosen from Christensenella massiliensis, Christensenella timonensis and / or Christensenella minuta and their mixture.
  • the invention also relates to a bacterium of the Christensenellaceae family for its use in the prevention and / or treatment of primary hypertriglyceridemia in humans or animals.
  • the bacteria are chosen from Christensenella massiliensis, Christensenella timonensis and / or Christensenella minuta and their mixture.
  • bacteria of the Christensenellaceae family when they are administered to a human being or an animal exhibiting hypertriglyceridemia, are capable of acting on the circulating triglycerides in excess during hypertriglyceridemia, and on lipoproteins LDL ("low density lipoproteins” low density lipoproteins and VLDL ("very low density lipoproteins” very low density lipoproteins).
  • LDL low density lipoproteins
  • VLDL very low density lipoproteins
  • the invention makes it possible to reduce the level of circulating triglycerides below the threshold of 150 mg / dL and that of LDL lipoproteins below the threshold of 1.6 g / L.
  • the bacteria or bacteria useful according to the invention are administered to humans or animals in an amount effective for an action on at least one of these molecules, i.e. to decrease the production of at least one of these molecules in the organ ism.
  • the bacteria or bacteria can be administered at a dose of 10 6 to 10 12 colony forming units (CFU) per day, regardless of the weight of the person or of the animal.
  • CFU colony forming units
  • it is a single dose, that is to say administered all at once or a dose before each meal, ie three times a day.
  • the bacterium of the Christensenellaceae family is also useful in the treatment of at least one disease caused by hypertriglyceridemia such as atherosclerosis or acute pancreatitis.
  • the bacteria or bacteria useful according to the invention are bacteria of the Christensenellaceae family, preferably of the genus Christensenella. It may in particular be Christensenella massiliensis, Christensenella timonensis and / or Christensenella minuta and their mixture. According to a particularly suitable variant, it is Christensenella minuta. According to another variant, they are Christensenella massiliensis and Christensenella timonensis or Christensenella massiliensis and Christensenella minuta or Christensenella timonensis and Christensenella minuta or Christensenella massiliensis and Christensenella timonensis and Christensenella minuta.
  • bacteria (s) useful according to the invention are preferably administered in a composition.
  • a subject of the invention is also a composition comprising at least one bacterium of the Christensenellaceae family in the prevention and / or treatment of hypertriglyceridemia in humans or animals.
  • a subject of the invention is also a composition comprising at least one bacterium and / or at least one protein and / or at least one nucleic acid originating from at least one bacterium of the Christensenellaceae family in the prevention and / or treatment of hypertriglyceridemia in humans or animals.
  • the bacteria or bacteria are present in an effective amount in the composition allowing an effect on the hypertriglyceridemia from which the treated persons or animals are affected.
  • the composition useful according to the invention comprises 10 6 to 10 12 colony-forming units (CFU) of bacteria of the Christensenellaceae family per daily dose of composition to be administered.
  • CFU colony-forming units
  • this corresponds to a daily dose of bacteria to be administered, whatever the weight of the person or the animal.
  • this dose is administered all at once.
  • composition useful according to the invention can be in liquid form. It may in particular comprise bacteria of the Christensenellaceae family and a culture medium for said bacteria which makes it possible to conserve them, such as, for example, preferably Columbia anaerobic agar medium enriched with sheep blood, or an equivalent medium containing no derivative of animal origin.
  • the composition useful according to the invention can be provided in solid form.
  • the bacteria can be present in lyophilized form, and can also include excipients such as, for example, microcrystalline cellulose, lactose, sucrose, fructose, levulose, starches, stachyose, raffinose, amylum , calcium lactate, magnesium sulfate, sodium citrate, calcium stearate, polyvinylpyrrolidone, maltodextrin, galactooligosaccharides, fructooligosaccharides, pectins, beta-glucans, lactoglobulins, isomaltooligosaccharides, polydextroses, sorbitol and / or glycerol.
  • excipients such as, for example, microcrystalline cellulose, lactose, sucrose, fructose, levulose, starches, stachyose, raffinose, amylum , calcium lactate,
  • compositions useful according to the invention can be provided in the form of powder, microencapsulated powder, gelatin capsule, capsule, tablet, lozenge, granules, emulsion, suspension or suppository. According to a particularly suitable embodiment, they can be in a gastro-resistant form, such as a coated tablet containing microencapsulated bacteria.
  • the bacteria can be used alive or inactivated, for example by heat, exposure to an appropriate pH, gamma rays or high pressure.
  • At least part of the bacteria consists of living bacteria, in particular at least 50% (by number), even more preferably at least 90% (by number).
  • the bacteria present in the composition useful according to the invention are at least 50% of living bacteria (by number), preferably for at least 90% of living bacteria (by number), even more preferably all alive.
  • the storage conditions according to the invention are provided for liquid formulations in the form of a frozen product maintained at -20 ° C. in an airtight sachet.
  • the storage conditions according to the invention comprise a capsule or a coating hermetic to light and to oxygen maintained at an ambient temperature of between 15 ° C and 40 ° C and a humidity of between 3% and 70%.
  • compositions useful according to the invention can be administered orally, topically, inhaled or rectally.
  • compositions useful according to the invention in addition to the bacteria useful according to the invention can comprise other compounds, such as:
  • At least one bacterium producing lactic acid which makes it possible to create an anaerobic environment favorable to Christensenellaceae, such as at least one bacterium chosen from bacteria of the genus Lactobacillus spp., Bifidobacterium spp., Streptococcus spp. and / or at least one other organism promoting the anaerobic conditions necessary for the survival of Christensenellaceae, such as at least one yeast chosen from Saccharomyces spp. or microorganisms of the Methanobacteriaceae family and / or
  • At least one bacterium associated with the ecosystem of Christensenellaceae because they facilitate their survival in the intestine such as at least one bacterium chosen from bacteria of the phylum Firmicutes, Bacteroidetes, Actinobacteria, Tenericutes, and Verrucomicrobia, and / or
  • At least one bacterium chosen from bacteria of the order Clostridales, Verrucomicrobiales, Aeromonadales, Alteromonadales, ML615J-28, RF32, YS2, from the Clostridiaceae family, Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, Enterococcaceae , Rikenéllaceae, Dehalobacteriaceae, Veillonellaceae and / or
  • Faecalibacterium chosen from bacteria of the genus Faecalibacterium, Akkermansia, Eubacterium, Turicibacter and Oscillospira such as, for example Faecalibacterium prausnitzii, Akkermansia muciniphila, Eubacterium halii, Turicibacter sanguinis, Oscillospira guilliermondii., and / or
  • At least one prebiotic such as for example at least one prebiotic chosen from galactooligosaccharides, fructooligosaccharides, inulins, arabinoxylans, beta-glucans, lactoglobulins and / or beta-caseins, and / or
  • At least one polyphenol such as for example at least one polyphenol chosen from quercetin, kaempferol, resveratrol, flavones (such as luteolin), flavan-3-ols (such as catechins), flavanones (such as narinenin) ), isoflavones, anthocyanidins, proanthocyanidins, and / or
  • At least one active pharmaceutical principle preferably chosen from omega 3, statins, fibrates, niacin.
  • the invention is now illustrated by examples of bacteria useful according to the invention, methods of culturing these bacteria, examples of compositions containing them and test results demonstrating the effectiveness of the invention.
  • Christensenella massiliensis can be cultivated according to the operating protocol described below. 1 / Prepare a carboxymethylcellulose (N 2 / C0 2 ) medium by following the following instructions provided by DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen).
  • Christensenella timonensis can be cultivated according to the same operating protocol as that described in Example 2 for Christensenella massiliensis.
  • Example 4 Useful composition according to the invention in liquid form
  • composition useful according to the invention in liquid form is a composition comprising Christensenella minuta 10 9 CFU / mL in the anaerobic RCM culture medium described above, modified to contain no product of animal origin and enriched in 5% glycerol. .
  • Example 4 The composition of Example 4 is obtained from an RCB (“research cell bank”) prepared on the basis of Christensenella minuta 10 10 CFU / mL then stored frozen at -20 ° C in an airtight bag. with oxygen.
  • RCB search cell bank
  • Example 5 Composition useful according to the invention in solid form
  • composition useful according to the invention in lyophilized form can be obtained by lyophilization of the composition of Example 4 in the frozen state.
  • the objective of this study is to evaluate the effects of bacteria of the Christensenellaceae family on hypertriglyceridemia.
  • the study was carried out blind: the experimenters did not know the treatments so that their previous knowledge did not influence the result of the study in any way.
  • mice Four week old male and female C57BI / 6 mice were purchased from Charles River (St Germain sur l'ArbresIe, France) and taken to the farm to begin a one week acclimatization period to the maintenance regimen. standard (Safe A04).
  • Animals were given ad libitum food and water for the duration of the study and were kept in a room at temperature (22.0 ⁇ 2.0 ° C) and humidity (40-50%). constant and illuminated on a 12h (8h - 20h) / 12h dark cycle.
  • a final blood sample was taken from the anesthetized animals (with a mixture of ketamine / xylazine 80/10 mg / kg). Blood samples were collected in centrifuge tubes pre-filled with heparin sulfate (200 IU / mL blood). Plasma was separated by centrifugation (B 500 rpm, 15 min at 4 ° C) and triglycerides were measured.
  • the objective of this study is to evaluate the effects of bacteria of the Christensenellaceae family on hepatic lipid metabolism.
  • the study was carried out in blind: the experimenters did not know the treatments so that their previous knowledge did not influence the outcome of the study in any way.
  • mice Four week old male C57BI / 6 mice were purchased from Charles River (St Germain sur l'ArbresIe, France) and received in the kennel to begin a one week acclimatization period to the standard maintenance regimen ( Safe A04).
  • Safe A04 the standard maintenance regimen
  • a control group remained on the standard maintenance diet (Safe A04) while the other 3 groups were placed on a high fat diet (“Research Diet D12451” 45% kcal noted HFDF45% in the figures).
  • liver samples (approximately 100 mg) were then ground in 1 ml of a 5% NP40 solution in ultra pure H20, and incubated for 5 min at 90 ° C. The samples were brought to room temperature to cool and incubated a second time at 90 ° C for 5 min to allow solubilization of TG and FFA. Supernatants containing TG and FFA were separated from the debris by centrifugation.
  • TG mice in normal diet (NC) or high in fat under different conditions of oral treatment (Vehicle (Veh), Orlistat, C. minuta) .
  • the objective of this study is to evaluate the effects of bacteria of the Christensenellaceae family on the molecular signals involved in the regulation of energy metabolism at the hepatic level.
  • the study was carried out blind: the experimenters did not know the treatments so that their previous knowledge did not influence the result of the study in any way.
  • mice Four week old male C57BI / 6 mice were purchased from Charles River (St Germain sur l'ArbresIe, France) and received in the kennel to begin a one week acclimatization period to the standard maintenance regimen ( Safe A04).
  • Safe A04 the standard maintenance regimen
  • a control group remained on the standard maintenance diet (Safe A04) while the other 3 groups were placed on a high fat diet (“Research Diet D12451” 45% kcal noted HFDF45% in the figures).
  • Animals were given ad libitum food and water for the duration of the study and were kept in a room at temperature (22.0 ⁇ 2.0 ° C) and humidity (40-50%). constant and illuminated on a 12h (8h - 20h) / 12h dark cycle.
  • Glucokinase is a hepatic enzyme catalyzing the first phosphorylation reaction of glucose necessary for its entry into glycolysis in the form of glucose-6-phosphate. It is therefore a key enzyme in the regulation of this catabolic pathway leading to the production of acetyl-CoA, the founding metabolic element at the origin of lipid synthesis. Gck has been shown to be overexpressed in response to a high fat diet in rodents [Tsukita, S., Yamada, T., Uno, K., Takahashi, K., Kaneko, K., Ishigaki, Y. et al. (2012).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP20725761.9A 2019-04-25 2020-04-24 Bakterium der familie christensenellaceae zur prävention und/oder behandlung von hypertriglyceridämie Pending EP3958882A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1904346A FR3095339A1 (fr) 2019-04-25 2019-04-25 Bactérie de la famille des Christensenellacées dans la prévention et/ou le traitement de l’hypertriglycéridémie
US201962839215P 2019-04-26 2019-04-26
PCT/EP2020/061510 WO2020216929A1 (fr) 2019-04-25 2020-04-24 Bactérie de la famille des christensenellacées dans la prévention et/ou le traitement de l'hypertriglycéridémie

Publications (1)

Publication Number Publication Date
EP3958882A1 true EP3958882A1 (de) 2022-03-02

Family

ID=70740567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20725761.9A Pending EP3958882A1 (de) 2019-04-25 2020-04-24 Bakterium der familie christensenellaceae zur prävention und/oder behandlung von hypertriglyceridämie

Country Status (3)

Country Link
US (1) US20230190824A1 (de)
EP (1) EP3958882A1 (de)
WO (1) WO2020216929A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178209A1 (en) * 2021-02-19 2022-08-25 Evelo Biosciences, Inc. Compositions and methods for treating metabolic diseases and disorders using christensenellaceae bacteria
AU2021439233A1 (en) * 2021-04-06 2023-11-23 Moon (guangzhou) Biotech Co., Ltd. Bacterial strain, composition, drug for use in combination and use
CN116919994B (zh) * 2023-09-15 2023-12-08 中国农业大学 小克里斯滕森氏菌在制备治疗多囊卵巢综合征的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206958B2 (en) * 2014-04-23 2019-02-19 Cornell University Modulation of fat storage in a subject by altering population levels of christensenellaceae in the GI tract
WO2016156527A1 (fr) * 2015-03-31 2016-10-06 International Nutrition Research Company Composition pour le traitement d'un etat metabolique pathogene du microbiote intestinal et des maladies derivees
EP3511407B1 (de) * 2016-09-06 2023-05-17 BGI Shenzhen Christensenella intestinihominis und anwendung davon
FR3063646B1 (fr) * 2017-03-10 2021-07-30 International Nutrition Res Company Bacteries specifiques pour leur utilisation comme medicament en particulier pour lutter contre le surpoids, l'obesite, les maladies cardiometaboliques et les maladies inflammatoires de l'intestin

Also Published As

Publication number Publication date
US20230190824A1 (en) 2023-06-22
WO2020216929A1 (fr) 2020-10-29

Similar Documents

Publication Publication Date Title
EP3937958A1 (de) <smallcaps/>? ? ?christensenellaceae? ? ? ? ?-bakterium der familie zur vorbeugung und/oder behandlung von chronischen entzündlichen erkrankungen und/oder entzündlichen gastrointestinalen erkrankungen und/oder krebs
EP3958882A1 (de) Bakterium der familie christensenellaceae zur prävention und/oder behandlung von hypertriglyceridämie
EP2931289B1 (de) Chitin oder derivate davon zur prävention und/oder behandlung von parasitosen
BE1028339B1 (fr) Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CA2893990C (fr) Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
CA3132239A1 (fr) Bacterie de la famille des christensenellacees dans la prevention et/ou le traitement de maladies inflammatoires chroniques et/ou de maladies gastro-intestinales inflammatoires et/ou de cancers
FR2906109A1 (fr) Complement alimentaire pour la prevention et la lutte contre les infections urinaires
CA3145274A1 (fr) Souches bacteriennes de faecalibacterium prausnitzii et de christensenella pour le traitement et la prevention d'une inflammation gastro-intestinale
EP2994100A1 (de) Petroselinsäure oder einer kombination von wirkstoffen mit mindestens petroselinsäure zur förderung von gewichtsverlust und/oder zur bewahrung des gewichts
FR3130557A1 (fr) Utilisation d’une souche bactérienne Limosilactobacillus fermentum seule ou en association avec Saccharomyces cerevisiae pour prévenir et/ou traiter les candidoses vaginales
EP4181938A1 (de) Kombination von lactobacillus-stämmen und verwendung davon in der tiergesundheit
FR3093642A1 (fr) Bactérie de la famille des Christensenellacées dans la prévention et/ou le traitement de maladies inflammatoires chroniques et/ou de cancers
FR3095339A1 (fr) Bactérie de la famille des Christensenellacées dans la prévention et/ou le traitement de l’hypertriglycéridémie
EP3989988B1 (de) Bakterium der familie christensenellaceae und diese enthaltende zusammensetzung zur vorbeugung und/oder behandlung von niereninsuffizienz
JP2007186529A (ja) 悪臭ガス放出減少方法
WO2022058423A1 (fr) Souche bacterienne appartenant au genre christensenella et compositions
EP3989990A1 (de) Bakterium der familie christellaceae und diese enthaltende zusammensetzung zur vorbeugung und/oder behandlung von pathologischem muskelschwund oder einer krankheit, die durch pathologischen muskelschwund gekennzeichnet ist
BE1028330B1 (fr) Composition comprenant de l'Akkermansia muciniphila et de l'extrait de camu camu
FR2974512A1 (fr) Composition anti-inflammatoire de l'intestin comprenant du maltitol
EP3979834A1 (de) Zusammensetzung mit einer hefe zur verhinderung einfacher und/oder wiederauftretender blasenentzündung
EP3989989A1 (de) Darmflorabakterien und diese enthaltende zusammensetzung zur vorbeugung und/oder behandlung von krankheiten, die durch überschüssiges 2-hydroxyglutarat gekennzeichnet sind
FR3138770A1 (fr) Ensemble de parties destine a moduler le microbiote intestinale, reduire la prise de poids et le stockage des graisses dans le foie
FR2741509A1 (fr) Composition dietetique absorbable susceptible d'ameliorer l'equilibre biologique de la flore du tractus intestinal
FR3078609A1 (fr) Composition pour diminuer la sensibilite au gluten
FR3078610A1 (fr) Composition de probiotiques particuliers et utilisation pour diminuer les symptomes inflammatoires digestifs

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211022

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VERB BIOTICS